{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:26:54Z","timestamp":1791599214832,"version":"4.3.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["Eli Lilly and Company"],"award-info":[{"award-number":["Eli Lilly and Company"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The Stool Frequency (SF) and Abdominal Pain (AP) items from the Crohn\u2019s Disease Activity Index are together referred to as the \u201cPatient Reported Outcome\u201d (PRO). The SF item measures the number of very soft\/liquid stools and the AP item measures abdominal pain severity, which are common Crohn\u2019s disease (CD) symptoms that patients consider important to treat. This study evaluated the psychometric properties of both PRO items separately and estimated thresholds for clinical remission in moderately to severely active CD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The measurement properties of the PRO items were analyzed using pooled data from VIVID-1 (NCT03926130), a Phase 3, randomized, placebo- and active-controlled study in adults with moderately to severely active CD. Analyses used weekly average scores of the SF and AP items at Weeks 0 (Baseline), 4, 12, and 52. Remission thresholds were estimated using the Patient Global Rating of Severity (PGRS) and Patient Global Impression of Change (PGIC) as primary anchors as well as qualitative evidence from exit interviews.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Data from 1065 participants (mean age: 36.2 years [standard deviation: 13 years]) were analyzed. During the trial, scores improved for both PRO items. Both items demonstrated moderate-to-good test-retest reliability for participants defined as stable based on PGRS and PGIC. Most correlations of related assessments were moderate (0.30\u2264|\u03c1<jats:italic>|<\/jats:italic> &lt;0.70) with SF and moderate-to-large (0.30\u2264|\u03c1<jats:italic>|<\/jats:italic> \u22640.90) with AP. By contrast, as anticipated, both items had weak correlations (|\u03c1<jats:italic>|<\/jats:italic> &lt;0.30) with endoscopic and laboratory assessments. The PRO items could discriminate between groups of participants known to differ based on other assessments. The PRO items were able to detect change, as score changes in both items between Baseline and Weeks 12 and 52 differed significantly between most PGRS and PGIC categories. Anchor-based analyses combined with responses from the exit interviews suggested that an SF score of \u2264\u20093 and an AP score of \u2264\u20091 could together represent clinical remission.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>These results support the reliability, construct-validity, and responsiveness of both PRO items in moderately to severely active CD and confirm previously suggested scores for both items that could represent clinical remission.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>Clinicaltrials.gov, NCT03926130. Registered 23 April 2019, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03926130\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT03926130<\/jats:ext-link>.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41687-025-00851-y","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:43:57Z","timestamp":1739839437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A patient-reported outcome measure comprising the stool frequency and abdominal pain items from the Crohn\u2019s Disease Activity Index: psychometric evaluation in adults with Crohn\u2019s disease"],"prefix":"10.1186","volume":"9","author":[{"given":"James D.","family":"Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1811-5370","authenticated-orcid":false,"given":"Aisha","family":"Vadhariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane K.","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Stassek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Clucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"issue":"9853","key":"851_CR1","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","volume":"380","author":"DC Baumgart","year":"2012","unstructured":"Baumgart DC, Sandborn WJ (2012) Crohn\u2019s disease. Lancet 380(9853):1590\u20131605. https:\/\/doi.org\/10.1016\/S0140-6736(12)60026-9","journal-title":"Lancet"},{"issue":"3","key":"851_CR2","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/j.gastro.2019.04.016","volume":"157","author":"D Piovani","year":"2019","unstructured":"Piovani D et al (2019) Environmental risk factors for inflammatory bowel diseases: an umbrella review of meta-analyses. Gastroenterology 157(3):647\u2013659. https:\/\/doi.org\/10.1053\/j.gastro.2019.04.016","journal-title":"Gastroenterology"},{"issue":"1","key":"851_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3748\/wjg.v30.i1.50","volume":"30","author":"AR Srinivasan","year":"2024","unstructured":"Srinivasan AR (2024) Treat to target in Crohn\u2019s disease: a practical guide for clinicians. World J Gastroenterol 30(1):50\u201369. https:\/\/doi.org\/10.3748\/wjg.v30.i1.50","journal-title":"World J Gastroenterol"},{"issue":"1","key":"851_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2020.18936","volume":"325","author":"K Cushing","year":"2021","unstructured":"Cushing K, Higgins PDR (2021) Management of Crohn Disease: a review. JAMA 325(1):69\u201380. https:\/\/doi.org\/10.1001\/jama.2020.18936","journal-title":"JAMA"},{"issue":"1","key":"851_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12955-022-01975-1","volume":"20","author":"A Nag","year":"2022","unstructured":"Nag A, Romero B (2022) Development and content validation of patient-reported outcomes tools for ulcerative colitis and Crohn\u2019s disease in adults with moderate-to-severe disease. Health Qual Life Outcomes 20(1):75. https:\/\/doi.org\/10.1186\/s12955-022-01975-1","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"851_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s11136-022-03233-9","volume":"32","author":"R Williams-Hall","year":"2023","unstructured":"Williams-Hall R et al (2023) A qualitative study to explore the symptoms and impacts of Crohn\u2019s disease and to develop the Crohn\u2019s Disease Diary. Qual Life Res 32(1):209\u2013223. https:\/\/doi.org\/10.1007\/s11136-022-03233-9","journal-title":"Qual Life Res"},{"issue":"3","key":"851_CR7","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/ecco-jcc\/jjab161","volume":"16","author":"WJ Sandborn","year":"2022","unstructured":"Sandborn WJ et al (2022) Association between proposed definitions of clinical remission\/response and well-being in patients with Crohn\u2019s Disease. J Crohns Colitis 16(3):444\u2013451. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab161","journal-title":"J Crohns Colitis"},{"issue":"3","key":"851_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/ecco-jcc\/jjv218","volume":"10","author":"D Farrell","year":"2016","unstructured":"Farrell D, McCarthy G, Savage E (2016) Self-reported symptom burden in individuals with inflammatory bowel disease. J Crohns Colitis 10(3):315\u2013322. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv218","journal-title":"J Crohns Colitis"},{"issue":"3","key":"851_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40271-019-00407-5","volume":"13","author":"E Louis","year":"2020","unstructured":"Louis E et al (2020) A qualitative research for defining meaningful attributes for the treatment of inflammatory bowel disease from the patient perspective. Patient 13(3):317\u2013325. https:\/\/doi.org\/10.1007\/s40271-019-00407-5","journal-title":"Patient"},{"issue":"21","key":"851_CR10","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","volume":"388","author":"EV Loftus Jr","year":"2023","unstructured":"Loftus EV Jr. et al (2023) Upadacitinib induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med 388(21):1966\u20131980. https:\/\/doi.org\/10.1056\/NEJMoa2212728","journal-title":"N Engl J Med"},{"issue":"9","key":"851_CR11","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","volume":"110","author":"L Peyrin-Biroulet","year":"2015","unstructured":"Peyrin-Biroulet L et al (2015) Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. J Am Coll Gastroenterol 110(9):1324\u20131338. https:\/\/doi.org\/10.1038\/ajg.2015.233","journal-title":"J Am Coll Gastroenterol"},{"key":"851_CR12","unstructured":"US Food and Drug Administration (2020) Patient-focused drug development: collecting comprehensive and representative input guidance for industry, food and drug administration staff, and other stakeholders [accessed March 2024]. https:\/\/www.fda.gov\/media\/139088\/download"},{"issue":"3","key":"851_CR13","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/s0016-5085(76)80163-1","volume":"70","author":"WR Best","year":"1976","unstructured":"Best WR et al (1976) Development of a Crohn\u2019s Disease Activity Index. Gastroenterology 70(3):439\u2013444. https:\/\/doi.org\/10.1016\/s0016-5085(76)80163-1","journal-title":"Gastroenterology"},{"issue":"2","key":"851_CR14","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1053\/gast.2002.31072","volume":"122","author":"WJ Sandborn","year":"2002","unstructured":"Sandborn WJ et al (2002) A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn\u2019s disease. Gastroenterology 122(2):512\u2013530. https:\/\/doi.org\/10.1053\/gast.2002.31072","journal-title":"Gastroenterology"},{"issue":"2","key":"851_CR15","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/ibd\/izz241","volume":"26","author":"JD Lewis","year":"2020","unstructured":"Lewis JD et al (2020) Correlation of stool frequency and abdominal pain measures with simple endoscopic score for Crohn\u2019s Disease. Inflamm Bowel Dis 26(2):304\u2013313. https:\/\/doi.org\/10.1093\/ibd\/izz241","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"851_CR16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","volume":"162","author":"BE Sands","year":"2022","unstructured":"Sands BE et al (2022) Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn\u2019s disease. Gastroenterology 162(2):495\u2013508. https:\/\/doi.org\/10.1053\/j.gastro.2021.10.050","journal-title":"Gastroenterology"},{"issue":"1","key":"851_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/apt.13001","volume":"41","author":"R Khanna","year":"2014","unstructured":"Khanna R et al (2014) A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn\u2019s disease activity. Aliment Pharmacol Ther 41(1):77\u201386. https:\/\/doi.org\/10.1111\/apt.13001","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"851_CR18","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1093\/ibd\/izx082","volume":"24","author":"B Feagan","year":"2018","unstructured":"Feagan B et al (2018) Performance of Crohn\u2019s disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: analysis of EXTEND Data. Inflamm Bowel Dis 24(5):932\u2013942. https:\/\/doi.org\/10.1093\/ibd\/izx082","journal-title":"Inflamm Bowel Dis"},{"key":"851_CR19","doi-asserted-by":"publisher","first-page":"S497","DOI":"10.14309\/00000434-201410002-01679","volume":"109","author":"C Gasink","year":"2014","unstructured":"Gasink C et al (2014) Evaluation of an interim Crohn\u2019s disease outcome measure (PRO\u2013\u20092) based on 2 patient-reported components (stool frequency, abdominal pain) of the Crohn\u2019s Disease Activity Index (CDAI) in the ustekinumab CERTIFI study: 1679. Am J Gastroenterol 109:S497","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"851_CR20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/ibd.21400","volume":"17","author":"K Thia","year":"2011","unstructured":"Thia K et al (2011) Short CDAI: development and validation of a shortened and simplified Crohn\u2019s disease activity index. Inflamm Bowel Dis 17(1):105\u2013111. https:\/\/doi.org\/10.1002\/ibd.21400","journal-title":"Inflamm Bowel Dis"},{"issue":"10470","key":"851_CR21","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/s0140-6736(24)01762-8","volume":"404","author":"M Ferrante","year":"2024","unstructured":"Ferrante M et al (2024) Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn\u2019s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. Lancet 404(10470):2423\u20132436. https:\/\/doi.org\/10.1016\/s0140-6736(24)01762-8","journal-title":"Lancet"},{"issue":"3","key":"851_CR22","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/0016-5085(89)90905-0","volume":"96","author":"G Guyatt","year":"1989","unstructured":"Guyatt G et al (1989) A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 96(3):804\u2013810","journal-title":"Gastroenterology"},{"issue":"4","key":"851_CR23","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/ibd.20301","volume":"14","author":"EJ Irvine","year":"2008","unstructured":"Irvine EJ (2008) Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis 14(4):554\u2013565. https:\/\/doi.org\/10.1002\/ibd.20301","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"851_CR24","first-page":"1571","volume":"91","author":"EJ Irvine","year":"1996","unstructured":"Irvine EJ, Zhou Q, Thompson AK (1996) The short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT investigators. Canadian Crohn\u2019s Relapse Prevention Trial. Am J Gastroenterol 91(8):1571\u20131578","journal-title":"Am J Gastroenterol"},{"key":"851_CR25","doi-asserted-by":"publisher","unstructured":"Shrout PE, Fleiss JL (1979) Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86(2):420\u2013428. https:\/\/doi.org\/10.1037\/\/0033-2909.86.2.420","DOI":"10.1037\/\/0033-2909.86.2.420"},{"key":"851_CR26","unstructured":"Hinkle DE, Wiersma W, Jurs SG (2003) Applied statistics for the behavioral sciences, 5th edn. Houghton Mifflin [Hi Marketing]"},{"key":"851_CR27","unstructured":"Scheff\u00e9 H (1959) The analysis of variance. Wiley"},{"key":"851_CR28","unstructured":"Cohen J (1988) Statistical Power Analysis for the behavioral sciences. Routledge. Routledge"},{"key":"851_CR29","doi-asserted-by":"publisher","unstructured":"D\u2019Haens GR et al (2022) Higher vs Standard Adalimumab Induction Dosing Regimens and\u00a0Two Maintenance Strategies: Randomized SERENE CD Trial\u00a0Results. Gastroenterology 162(7):1876\u20131890. https:\/\/doi.org\/10.1053\/j.gastro.2022.01.044","DOI":"10.1053\/j.gastro.2022.01.044"},{"issue":"Supplement1","key":"851_CR30","doi-asserted-by":"publisher","first-page":"i1353","DOI":"10.1093\/ecco-jcc\/jjad212.0850","volume":"18","author":"T Hunter-Gibble","year":"2024","unstructured":"Hunter-Gibble T et al (2024) P720 exit interviews exploring Crohn\u2019s disease patients\u2019 experience of changes in their bowel urgency during the mirikizumab phase 3 clinical trial in adult patients with moderate to severe Crohn disease. J Crohn\u2019s Colitis 18(Supplement1):i1353\u2013i1354. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad212.0850","journal-title":"J Crohn\u2019s Colitis"},{"issue":"5","key":"851_CR31","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D et al (2021) STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 160(5):1570\u20131583. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.031","journal-title":"Gastroenterology"},{"issue":"6","key":"851_CR32","doi-asserted-by":"publisher","first-page":"e0156666","DOI":"10.1371\/journal.pone.0156666","volume":"11","author":"J Zeitz","year":"2016","unstructured":"Zeitz J et al (2016) Pain in IBD patients: very frequent and frequently insufficiently taken into account. PLoS ONE 11(6):e0156666. https:\/\/doi.org\/10.1371\/journal.pone.0156666","journal-title":"PLoS ONE"},{"issue":"1","key":"851_CR33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/meg.0000000000001568","volume":"32","author":"DR Hoekman","year":"2020","unstructured":"Hoekman DR et al (2020) A prospective study comparing patient-reported outcomes in Crohn\u2019s disease. Eur J Gastroenterol Hepatol 32(1):38\u201344. https:\/\/doi.org\/10.1097\/meg.0000000000001568","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"12","key":"851_CR34","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1136\/gutjnl-2016-312307","volume":"66","author":"JF Colombel","year":"2017","unstructured":"Colombel JF et al (2017) Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. Gut 66(12):2063\u20132068. https:\/\/doi.org\/10.1136\/gutjnl-2016-312307","journal-title":"Gut"},{"issue":"2","key":"851_CR35","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5217\/ir.2021.00064","volume":"20","author":"N Kamat","year":"2022","unstructured":"Kamat N et al (2022) Correlation of fecal calprotectin and patient-reported outcome measures in patients with ulcerative colitis. Intest Res 20(2):269\u2013273. https:\/\/doi.org\/10.5217\/ir.2021.00064","journal-title":"Intest Res"},{"issue":"9","key":"851_CR36","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/apt.13387","volume":"42","author":"B Jharap","year":"2015","unstructured":"Jharap B et al (2015) Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis. Aliment Pharmacol Ther 42(9):1082\u20131092. https:\/\/doi.org\/10.1111\/apt.13387","journal-title":"Aliment Pharmacol Ther"},{"key":"851_CR37","unstructured":"US Food and Drug Administration (2009) Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims [accessed May 2024]. https:\/\/www.fda.gov\/media\/77832\/download"},{"issue":"9","key":"851_CR38","doi-asserted-by":"publisher","first-page":"e73990","DOI":"10.1371\/journal.pone.0073990","volume":"8","author":"S Vaz","year":"2013","unstructured":"Vaz S et al (2013) The case for using the repeatability coefficient when calculating test-retest reliability. PLoS ONE 8(9):e73990. https:\/\/doi.org\/10.1371\/journal.pone.0073990","journal-title":"PLoS ONE"},{"key":"851_CR39","unstructured":"US Food and Drug Administration (2019) Incorporating clinical outcome assessments into endpoints for regulatory decision-making [accessed May 2024]. https:\/\/www.fda.gov\/media\/132505\/download"},{"key":"851_CR40","unstructured":"National Library of Medicine (2023) NCT03926130. A study of mirikizumab (LY3074828) in participants with Crohn\u2019s disease (VIVID-1) [accessed May 2024]. https:\/\/www.clinicaltrials.gov\/study\/NCT03926130"},{"key":"851_CR41","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1477-7525-4-70","volume":"4","author":"DA Revicki","year":"2006","unstructured":"Revicki DA et al (2006) Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes 4:70. https:\/\/doi.org\/10.1186\/1477-7525-4-70","journal-title":"Health Qual Life Outcomes"},{"key":"851_CR42","doi-asserted-by":"publisher","unstructured":"Kopcakova J et al (2020) Test-retest reliability of a questionnaire on motives for physical activity among adolescents. Int J Environ Res Public Health 17(20). https:\/\/doi.org\/10.3390\/ijerph17207551","DOI":"10.3390\/ijerph17207551"},{"issue":"3","key":"851_CR43","doi-asserted-by":"publisher","first-page":"A40","DOI":"10.1016\/j.jval.2013.03.230","volume":"16","author":"N Quadri","year":"2013","unstructured":"Quadri N et al (2013) A literature review of the variance in interval length between administrations for assessment of test retest reliability and equivalence of pro measures. Value Health 16(3):A40\u2013A41. https:\/\/doi.org\/10.1016\/j.jval.2013.03.230","journal-title":"Value Health"},{"key":"851_CR44","doi-asserted-by":"crossref","unstructured":"Streiner DL, Norman GR, Cairney J (2014) Health Measurement scales: a practical guide to their development and use. Oxford University Press","DOI":"10.1093\/med\/9780199685219.001.0001"},{"issue":"1","key":"851_CR45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jclinepi.2006.03.012","volume":"60","author":"CB Terwee","year":"2007","unstructured":"Terwee CB et al (2007) Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 60(1):34\u201342. https:\/\/doi.org\/10.1016\/j.jclinepi.2006.03.012","journal-title":"J Clin Epidemiol"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00851-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-025-00851-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00851-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:44:07Z","timestamp":1739839447000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-025-00851-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["851"],"URL":"https:\/\/doi.org\/10.1186\/s41687-025-00851-y","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"29 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was compliant with the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical guidelines and the International Conference on Harmonization guidelines on Good Clinical Practice. All informed consent forms and protocols were approved by appropriate ethical review boards before initiation of the study. All participants provided written informed consent before any study procedures were performed and before study drug administration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JDL consulted or served on an advisory board for AbbVie, Amgen, Arena Pharmaceuticals, Bridge Biotherapeutics, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Entasis Therapeutics, Galapagos, Gilead, Janssen Pharmaceuticals, Samsung Bioepis, Merck, Nestle Health Science, UCB, Pfizer, Protagonist Therapeutics, Sanofi, and Scipher Medicine. He has had research funding from Nestle Health Science, Takeda, Janssen Pharmaceuticals, and AbbVie. He has had educational grants from Takeda and Janssen. He has performed legal work on behalf of generic manufacturers of ranitidine and 3\u00a0M. He owns stock in Dark Canyon Labs. AV, S Su, and FD are employees and shareholders of Eli Lilly and Company. XZ is an employee of Syneos Health, which received funding from Eli Lilly and Company in connection with this study. AKK, LS, and CC are employees of Evidera, which received funding from Eli Lilly and Company in connection with this study. S Schreiber has been a consultant for AbbVie, Amgen, Arena Pharmaceuticals, Bristol Myers Squibb, Boehringer Ingelheim, Celltrion, Dr Falk Pharma, Ferring, Fresenius, Galapagos, Genentech, GSK, Gilead, I-MAB Biopharma, Janssen, Eli Lilly and Company, Merck, Novartis-Sandoz, Pfizer, Protagonist, Takeda, and Theravance.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}